Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 201.72% | RBC Capital | → $7 | Initiates Coverage On | → Outperform |
| 07/31/2023 | 546.55% | EF Hutton | → $15 | Initiates Coverage On | → Buy |
| 03/23/2023 | 503.45% | Credit Suisse | → $14 | Reiterates | → Outperform |
| 11/02/2021 | 589.66% | B of A Securities | → $16 | Initiates Coverage On | → Neutral |
| 11/02/2021 | 977.59% | Jefferies | → $25 | Initiates Coverage On | → Buy |
| 11/02/2021 | 718.97% | Credit Suisse | → $19 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/05/2023 | 201.72% | 加拿大皇家銀行資本 | →$7 | 開始承保 | →跑贏大盤 |
| 07/31/2023 | 546.55% | EF Hutton | →$15 | 開始承保 | →購買 |
| 03/23/2023 | 503.45% | 瑞士信貸 | →$14 | 重申 | →跑贏大盤 |
| 11/02/2021 | 589.66% | B of A證券 | →$16 | 開始承保 | →中性 |
| 11/02/2021 | 977.59% | 傑富瑞 | →$25 | 開始承保 | →購買 |
| 11/02/2021 | 718.97% | 瑞士信貸 | →$19 | 開始承保 | →跑贏大盤 |
What is the target price for Pyxis Oncology (PYXS)?
Pyxis Oncology(PYXS)的目標價格是多少？
The latest price target for Pyxis Oncology (NASDAQ: PYXS) was reported by RBC Capital on September 5, 2023. The analyst firm set a price target for $7.00 expecting PYXS to rise to within 12 months (a possible 201.72% upside). 3 analyst firms have reported ratings in the last year.
加拿大皇家銀行資本於2023年9月5日報道了Pyxis Oncology(納斯達克：PYXS)的最新目標價。這家分析公司將目標價定為7美元，預計PYXS將在12個月內上漲至(可能上漲201.72%)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Pyxis Oncology (PYXS)?
Pyxis Oncology(PYXS)最近的分析師評級是多少？
The latest analyst rating for Pyxis Oncology (NASDAQ: PYXS) was provided by RBC Capital, and Pyxis Oncology initiated their outperform rating.
納斯達克(Sequoia Capital：PYXS)對PYXIS腫瘤學的最新分析師評級是由加拿大皇家銀行資本提供的，PYXIS腫瘤學發起了其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Pyxis Oncology (PYXS)?
Pyxis Oncology(PYXS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pyxis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pyxis Oncology was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Pyxis Oncology的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Pyxis腫瘤學的上一次評級是在2023年9月5日提交的，所以你應該預計下一次評級將在2024年9月5日左右的某個時候提供。
Is the Analyst Rating Pyxis Oncology (PYXS) correct?
分析師對Pyxis Oncology(PYXS)的評級正確嗎？
While ratings are subjective and will change, the latest Pyxis Oncology (PYXS) rating was a initiated with a price target of $0.00 to $7.00. The current price Pyxis Oncology (PYXS) is trading at is $2.32, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Pyxis Oncology(PYXS)評級是以0.00美元至7.00美元的目標價啟動的。目前Pyxis Oncology(PYXS)的交易價格為2.32美元，在分析師的預測範圍內。